STAT1d
Biotech feud over the multibillion-dollar cancer blood test market spills onto social media
A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...
bovnews1d
Wells Fargo Issues Overweight Rating for Exact Sciences Corp (EXAS) Stock
Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $69.21 which represents a slight increase of $1.22 or 1.79% from the prior close of $67.99. The stock opened at $68.14 and ...
Buy Rating Affirmed for Exact Sciences on Robust CRC Test Results and Strategic Pipeline Advancements
Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...
FiercePharma4d
Exact Sciences debuts first Spanish-language Cologuard ads to drive colon cancer screening in Latino community
Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign ...
Exact Sciences Unusual Options Activity For September 16
In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...
Buy Rating for Exact Sciences: Promising CRC Screening Test Outperforms with High Accuracy and Market Potential
Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...
Becker's ASC3d
Blood-based colorectal cancer tests show 88% sensitivity
New data from cancer screening and diagnostic test provider Exact Sciences have shown an 88.3% sensitivity rate for its blood-based colorectal cancer screening test.